Login to Your Account



Biomarin NDA done, Sarepta next in line as therapies 'bottleneck'

By Randy Osborne
Staff Writer

Tuesday, April 28, 2015

On schedule, Biomarin Pharmaceutical Inc. this week finished off the rolling NDA for exon 51-skipping drisapersen to treat DMD, situating the firm a few months ahead of Sarepta Therapeutics Inc. 

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription